Blog
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Coinsilium Group Limited: Result of AGM and Statement
Coinsilium Group Limited: Result of AGM and Statement
Romande Energie promoting biomass as reused energy source and supporting start-up Proxipel
Romande Energie promoting biomass as reused energy source and supporting start-up Proxipel
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
EQS-News: GRENKE achieves top ranking in DVFA’s Corporate Governance Scorecard
EQS-News: GRENKE achieves top ranking in DVFA’s Corporate Governance Scorecard
Aroundtown SA: Release of a capital market information
Aroundtown SA: Release of a capital market information
EQS-News: Corestate appoints Stephan Goetschel as CRO to the Group Management Board
EQS-News: Corestate appoints Stephan Goetschel as CRO to the Group Management Board
Polymetal: Results of the first tranche of the Exchange Offer
Polymetal: Results of the first tranche of the Exchange Offer
EQS-News: Eurobattery Minerals AB: Metallurgical study in Corcel confirms high level of Nickel worth EUR 113.9 million
EQS-News: Eurobattery Minerals AB: Metallurgical study in Corcel confirms high level of Nickel worth EUR 113.9 million
Impairment of Kairos goodwill following unprecedented difficult year for active asset managers
Impairment of Kairos goodwill following unprecedented difficult year for active asset managers
Helvetia (CH) Swiss Property Fund delivers another successful set of results for 2021/22
Helvetia (CH) Swiss Property Fund delivers another successful set of results for 2021/22
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
Fuller, Smith & Turner PLC: Transaction in Own Shares
Fuller, Smith & Turner PLC: Transaction in Own Shares
Rights and Issues Investment Trust PLC: Transaction in Own Shares
Rights and Issues Investment Trust PLC: Transaction in Own Shares
EQS-Adhoc: va-Q-tec AG: Prospectively near-term conclusion of a Business Combination Agreement with EQT Private Equity and approval of a cash capital increase without subscription rights of approx. 10%
EQS-Adhoc: va-Q-tec AG: Prospectively near-term conclusion of a Business Combination Agreement with EQT Private Equity and approval of a cash capital increase without subscription rights of approx. 10%
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: RPS Group plc
Form 8.3 - The Vanguard Group, Inc.: RPS Group plc